GlassScriptPhysician profile
Seth Tyler Koehler
NPI 1255782843
$2,114.76
in general payments reported to CMS, 2019-2025
23 companies · $1,378 in 2025
The $1,378 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.33 · 2020: $21.73 · 2024: $694 · 2025: $1,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,033 · Education: $39.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,032.63 |
| Education | $39.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $413.81 | 2024-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $374.13 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $251.90 | 2024-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $153.68 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.47 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $124.12 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $96.02 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.89 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $63.84 | 2024-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Dexcom, INC. | $51.98 | 2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $46.26 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.24 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $38.28 | 2024-2025 | Cologuard Collection Kit |
| Seqirus USA INC | $33.98 | 2024 | Flucelvax, Fluad |
| Janssen Pharmaceuticals, INC | $27.25 | 2025 | Spravato |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $21.99 | 2025 | Gemtesa |
| Pulmonx Corporation | $21.73 | 2020 | |
| Depuy Synthes Sales INC. | $21.33 | 2019 | |
| Phathom Pharmaceuticals, INC. | $20.79 | 2024 | Voquezna |
| Viatris Specialty LLC | $18.92 | 2025 | Yupelri |
| Mylan Specialty L.P. | $18.63 | 2024 | Yupelri |
| Grifols USA, LLC | $17.96 | 2024 | Prolastin-C Liquid |
| Pfizer INC. | $13.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Koehler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.